12 March 2017. Commons Network responded to the European Commission Public stakeholder consultation on the interim evaluation of Horizon 2020 as well as to the public stakeholder consultation on the Innovative Medicines Initiative.
In both cases we focus on the need for clear public return on public investment, and the production of public knowledge goods. Currently most knowledge developed with the support of these EU initiatives is privatised. Instead when funding R&D into medical technologies, Horizon 2020 and IMI should explore new models of innovation, based on the de-linkage of the incentive to innovate from the price of the resulting medical technology.
See our Horizon 2020 response here.
See our IMI response here.